On December 30, 2021 Blueprint Medicines Corporation (NASDAQ: BPMC) reported that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG-451, a potential best-in-class oral precision therapy in development for the treatment of non-small cell lung cancer (NSCLC) in patients with EGFR exon 20 insertion mutations (Press release, Blueprint Medicines, DEC 30, 2021, View Source [SID1234597852]). An investigational new drug (IND) application for LNG-451 was submitted to the U.S. Food and Drug Administration (FDA) by Lengo Therapeutics in December 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The acquisition of Lengo Therapeutics and its lead candidate LNG-451 enables Blueprint Medicines to expand our pipeline in lung cancer and harness our experience and expertise to advance precision oncology therapies for the patients who need them," said Fouad Namouni, M.D., President of Research & Development. "I want to thank the Lengo Therapeutics team, again for their work to advance the highly selective therapeutic candidate LNG-451, but also for completing the IND submission with a continued sense of urgency. Pending FDA clearance of the application, we plan to advance LNG-451 into the clinic in the first quarter of 2022."

As previously disclosed, under the terms of the agreement, Blueprint Medicines acquired Lengo Therapeutics for $250 million in cash plus up to $215 million in additional potential payments based on the achievement of certain regulatory approval and sales-based milestones.

On December 30, 2021 Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as "Sumgen") reported that it has completed the series B + funding with over RMB 200 million (Press release, Sumgen Biotech, DEC 30, 2021, View Source;a=nav&id=247 [SID1234656269]). This funding is jointly invested by Junchuan Capital, Zheshang Venture Capital, Qianhai Wanhui and Wuxi Shangtong, and the existing investors Sinopharm CNBG, Hankang Capital and Addor Capital continue to add on. StartPointAdvisors has served as the exclusive financial adviser for this round of financing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sumgen is an innovation-driven biopharmaceutical company, which is committed to the development and commercialization of innovative antibody drugs for major diseases such as tumors. The company has continuous innovation capability and product export capability, and has established several innovation platforms, including several antibody discovery platforms such as mammalian cell display platform and BIMA (BI-specific/functional Macrophage Activator), BITA(BI-specific/functional T cell Activator).

Around the field of cancer, Sumgen has focused on the layout of a series of innovative products. SG301, SG404, SG12473 and other projects have completed the double report between China and the United States, entered the clinical study stage, and made positive progress; In November 2021, SG2501, the world’s first anti-CD38/CD47 bispecific antibody drug wholly developed by the company, was approved by FDA to carry out clinical study, and the clinical preparations for this project in the United States are progressing steadily. The company has carried out a global patent layout for innovative antibody drugs and declared more than 60 invention patents; and reached a number of commercial cooperations with CSPC and Sinopharm CNGB. At present, the company has started the construction of international standard production base, and is committed to providing high-quality Chinese antibodies for patients all over the world.

Dr. Lv Ming, founder and CEO of Sumgen, said: "Thanks to the new and old shareholders for their support to Sumgen. Sumgen will deepen the development of innovative products and accelerate the clinical layout in an all-round way; strengthen the sustainable source innovation ability and drive the development of enterprises with innovation; build industrial transformation ability and commercialization ability, and help enterprises build the whole industrial chain. "

On December 30, 2021 Sirnaomics Ltd. ("Sirnaomics" or "Company", together with its subsidiaries, the "Group", stock code: 2257.HK), the RNA therapeutics biopharmaceutical company with strong presence in both the U.S. and China, and the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics, reported that it is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") (Press release, Sirnaomics, DEC 30, 2021, View Source [SID1234597853]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The product pipeline of Sirnaomics has over a dozen of candidates for a wide range of therapeutic indications across rare diseases and diseases with large patient populations covering oncology, fibrosis, medical aesthetics, antiviral, cardiometabolic diseases and other fields. Its product candidates currently span all stages from preclinical research and IND-enabling studies to Phase I and Phase II clinical trials, creating an enriched portfolio and an extended timeline of product candidates. The proprietary delivery platforms for administration of RNA-based therapeutics are the foundation Sirnaomics’ pipeline, and the related proprietary PNP and novel GalNAc delivery platforms confer advantages over conventional delivery platforms. The Company believes its highly innovative RNAi delivery platforms set Sirnaomics in a class by itself. The PNP delivery platform allows delivery of both siRNA and mRNA to diseased cells via local or systemic administration, providing distinct advantages in low toxicity, easy manufacturing and the capability to reach many targeted organs and cell types. The results of Phase IIa clinical trial in oncology validate both the effectiveness of its PNP delivery platform and the therapeutic targets for isSCC, positioning the Company for accelerated development of other pipeline products using the same PNP delivery platform. The Company’s core product candidate STP705, another clinical stage product candidate STP707, and at least eight other preclinical candidates all utilize the PNP delivery platform. RNAimmune, a controlled subsidiary of Sirnaomics, also applies PNP and a related proprietary delivery platform based on polypeptide-lipid nanoparticles (PLNP), to develop mRNA-based therapeutics and vaccines.

Dr. Patrick Y. Lu, Founder, Chairman of Board, President and CEO of Sirnaomics said, "Today marked a significant milestone in Sirnaomics’ history. Our successful debut in the Hong Kong stock market shows global investors’ profound recognition for our strategic model, growth potential, proprietary and novel drug delivery platforms, rich product pipeline and experienced management team. We are so proud and would like to express our sincere gratitude to investors for their trust and support to Sirnaomics. We are committed to becoming a fully-integrated international biopharmaceutical company. Leveraging its deep experience in RNA therapeutics and novel delivery platform technologies, the Company will continuously advance the development of innovative therapeutic modalities for the treatment of a broad range of diseases and strengthen our intellectual properties to maximize the clinical potential to rapidly discover, develop and commercialize more transformative therapeutics and vaccines for patients around the world."

On December 30, 2021 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, reported that Gritstone management will participate in the following upcoming investor conferences in January (Press release, Gritstone Oncology, DEC 30, 2021, View Source [SID1234597854]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference: JP Morgan 40th Annual Global Healthcare Conference
Presentation Date and Time: Thursday, January 13, 2022 at 8:15 a.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president, and chief executive officer

Conference: H.C. Wainwright BioConnect Conference 2022
Presentation Date and Time: Available beginning Monday, January 10, 2022 at 7:00 a.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president, and chief executive officer

Conference: B. Riley Securities’ 2022 Virtual Oncology Conference
Presentation Date and Time: Thursday, January 27, 2022 at 1:30 p.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president, and chief executive officer

Live webcasts of all presentations will be accessible via the Investors & Media section of the company’s website at View Source An archived replay will be accessible for 30 days following each event.

On December 30, 2021 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, reported that it will present virtually at the 2022 Goldman Healthcare CEOs Unscripted Conference on Thursday, January 6, 2022, at 9:00 a.m. (EDT) (Press release, Thermo Fisher Scientific, DEC 30, 2021, View Source [SID1234597858]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com.